Find a UK-based prescribing clinician for medical cannabis.
Medically reviewed: May 2026
Post-traumatic stress disorder (PTSD) affects an estimated 4% of the UK population at any given time — roughly 2.7 million people. Among military veterans, emergency service workers and survivors of serious trauma, the prevalence is considerably higher. Despite decades of research into cognitive-behavioural therapy (CBT), eye movement desensitisation and reprocessing (EMDR) and pharmacological treatments, a significant proportion of patients do not achieve adequate relief with conventional approaches. Medical cannabis has emerged globally as one of the most frequently requested indications in cannabis-based medicine programmes, and the UK is no exception.
Since November 2018, specialist doctors in England, Scotland, Wales and Northern Ireland have been legally permitted to prescribe cannabis-based medicinal products (CBMPs) for patients with a clinical need. PTSD sits within a broader category of conditions where prescribing clinics have accumulated growing real-world experience. This guide summarises the current clinical evidence, explains what UK patients can realistically expect, and outlines the practical steps involved in accessing a prescription.
Clinical Evidence for Cannabis in PTSD
The evidence base for cannabis-based treatments in PTSD has grown substantially over the past decade, drawing on data from Canada, Israel, the United States and, increasingly, the UK itself.
One of the most cited bodies of work originates from the Canadian Armed Forces, where veterans with service-related PTSD have been permitted to access medical cannabis since 2015. Retrospective analyses consistently found reductions in nightmare frequency, improvements in sleep continuity and decreased hyperarousal scores among participants using THC-containing products at night. A landmark paper published in Frontiers in Pharmacology (2018) reviewed the neurobiological rationale, noting that the endocannabinoid system plays a direct role in fear extinction — the process by which the brain learns to contextualise traumatic memories rather than reactivating them as live threats. CB1 receptors are densely concentrated in the amygdala and prefrontal cortex, brain regions central to emotional regulation and threat appraisal in PTSD.
Israeli military researchers have contributed several prospective studies examining THC:CBD balanced products in combat veterans. Outcomes measured across these studies include PTSD Checklist (PCL-5) scores, Pittsburgh Sleep Quality Index results and frequency of trauma-related nightmares. Improvements in all three domains were reported, with the most consistent signal in sleep architecture and nightmare suppression.
In the UK, Project TWENTY21 — a real-world evidence registry run by Drug Science — enrolled over 5,000 patients between 2020 and 2023 across multiple conditions including PTSD. Interim data published in 2022 showed that PTSD patients reported statistically significant improvements in health-related quality of life at three and six months, with anxiety, sleep and overall wellbeing as the primary drivers. The PTSD cohort in TWENTY21 was among those showing the most consistent patient-reported benefit.
It is important to note that randomised controlled trial (RCT) data specifically for cannabis in PTSD remains limited, largely due to historic regulatory barriers on research cannabis. NICE guidance does not currently recommend CBMPs for PTSD as a first-line treatment, but acknowledges the emerging evidence base. Many specialist clinicians treat PTSD as a legitimate indication where conventional options have been exhausted.
Why PTSD Patients Turn to Medical Cannabis
Understanding why patients seek cannabis-based treatment requires an honest assessment of what conventional PTSD care looks like in the UK in 2026.
NHS Talking Therapies (formerly IAPT) offers trauma-focused CBT and EMDR, both recommended by NICE guideline NG116 as first-line psychological treatments. However, waiting times for trauma-specialist therapy routinely exceed 18 months in many NHS trusts, with some patients reporting waits of two years or longer. Private EMDR therapy is effective but expensive: sessions typically cost £80–150 each, and a full treatment course may require 12–20 sessions.
First-line pharmacological treatment for PTSD in the UK centres on SSRIs (sertraline and paroxetine are NICE-approved) and the noradrenaline reuptake inhibitor venlafaxine. Response rates are moderate; meta-analyses suggest roughly 40–60% of patients achieve a meaningful reduction in symptoms with optimised SSRI treatment, leaving a substantial group with refractory or partially responsive PTSD. Prazosin, an alpha-1 blocker used off-label to reduce PTSD-related nightmares, is widely prescribed in North American veteran populations but has limited uptake in UK primary care.
For patients who have tried multiple antidepressants, completed a course of therapy, and still experience intrusive flashbacks, hypervigilance, emotional numbing and fragmented sleep, the threshold to seek alternative options lowers significantly. Medical cannabis represents, for many, not a first choice but a carefully considered option after years of inadequate symptom control.
THC vs CBD for PTSD: What UK Clinicians Prescribe
UK prescribing clinics have moved away from a one-size-fits-all approach to PTSD. The prescription profile depends on symptom predominance, tolerance, previous cannabis experience and time of use.
For patients whose primary complaint is fragmented sleep, trauma-related nightmares and evening hyperarousal, low-to-moderate THC flower or THC-dominant oils are commonly initiated at night. THC acts on CB1 receptors in the hypothalamus and limbic system in ways that reduce REM sleep dreaming intensity — the phase in which traumatic nightmares most commonly occur. Starting doses are kept low (1–2mg THC via vaporisation) and titrated gradually under clinical supervision.
Balanced THC:CBD products — for example, a 1:1 oil — are frequently used where patients experience daytime anxiety, irritability or emotional dysregulation. CBD modulates CB1 receptor activity without direct agonism, and preclinical evidence suggests it may facilitate fear extinction processes. Daytime CBD-dominant oils can support anxiety management without the cognitive effects associated with higher-THC formulations.
Pure CBD oils, available as unlicensed CBMPs or as over-the-counter supplements, have limited evidence specifically for PTSD but are sometimes incorporated into a broader treatment plan for patients who are THC-naive or who have occupational constraints on psychoactive medication.
For detailed information on the specific product types available in the UK, visit our cannabis strains and products guide.
Getting a PTSD Cannabis Prescription in the UK
The pathway to a cannabis prescription for PTSD in the UK is straightforward in principle, though it requires preparation. Here is what to expect step by step.
Step 1: Confirm your diagnosis. You need a formal PTSD diagnosis from a qualified clinician — a GP letter, a psychiatric assessment or documented treatment history (including SSRI prescriptions) are all acceptable. If you have completed NHS Talking Therapies and have a discharge summary, this is particularly useful.
Step 2: Complete a PCL-5 self-assessment. Most UK prescribing clinics ask patients to complete the PTSD Checklist (PCL-5) before or during the initial consultation. A score of 33 or above is indicative of clinically significant PTSD and supports prescribing eligibility. Your score helps the clinician establish a baseline and track treatment response.
Step 3: Book an initial specialist consultation. Initial appointments with UK cannabis clinics typically cost £150–250 and last 45–60 minutes. The specialist (usually a psychiatrist, anaesthetist or pain specialist) will review your diagnosis, treatment history and symptom profile. They will discuss realistic expectations, risks and the proposed treatment plan.
Step 4: Receive your prescription and pharmacy referral. If the specialist proceeds, a prescription is issued to a licensed UK pharmacy. Most cannabis prescriptions require a Schedule 2 controlled drug form. Your medication is typically dispensed within 3–5 working days.
Step 5: Follow-up appointments. Ongoing prescriptions require regular follow-up, usually monthly for the first three months and quarterly thereafter. Dose adjustments are made based on symptom response and any reported side effects.
To begin the process, use our Find a Doctor tool to locate a PTSD-experienced cannabis specialist near you.
UK Veterans and Medical Cannabis
Military veterans represent a disproportionately large segment of the UK’s PTSD population. Studies consistently estimate PTSD prevalence at 6–8% in UK veterans who have served in operational roles, with rates significantly higher among those deployed to Iraq and Afghanistan.
The NHS provides veteran-specific mental health support through Op Courage — The Veterans Mental Health and Wellbeing Service, which offers trauma-focused assessment and therapy with clinicians trained in veteran experiences. Op Courage is available across all four nations and does not require a GP referral. However, its reach is limited and therapy waiting times remain a challenge in many areas.
A number of UK charities — including Combat Stress, Help for Heroes and Veterans UK — have produced materials acknowledging the increasing use of medical cannabis among veterans. The Veterans’ Cannabis Map, an informal resource developed by patient advocates, documents dispensing pharmacies and veteran-friendly clinics across the UK.
For veterans seeking private access, the pathway is identical to the civilian route described above. Some clinics have developed veteran-specific assessment pathways that incorporate military occupational history and deployment-related trauma frameworks. Evidence from North American veteran programmes suggests that veterans who access cannabis treatment in a structured clinical setting — with regular follow-up and PCL-5 monitoring — achieve better outcomes than those who self-medicate without medical supervision.
It is worth noting that veterans receiving pension payments or benefits related to a PTSD diagnosis should seek advice on whether private medical treatment may affect their entitlement status before proceeding.
Cost and Access
Medical cannabis is not currently available on the NHS for PTSD. All prescriptions are issued privately, meaning costs are borne by the patient. The following table provides a realistic breakdown of typical expenses.
| Item | Typical Cost | Frequency |
|---|---|---|
| Initial specialist consultation | £150 – £250 | Once |
| Follow-up appointment (months 1–3) | £50 – £100 | Monthly |
| Quarterly follow-up (ongoing) | £50 – £100 | Every 3 months |
| Monthly medication (flower/oil) | £150 – £400 | Monthly |
| Dry herb vaporiser (if required) | £80 – £200 | One-off purchase |
Total first-year costs therefore typically fall between £2,200 and £5,500 depending on the dosing regimen. For context, a full private EMDR therapy course (16 sessions at £100 per session) costs approximately £1,600 — but many PTSD patients have already completed multiple therapy courses before seeking cannabis treatment.
Some private health insurance policies in the UK have begun to cover cannabis prescriptions under specialist mental health provisions. It is worth contacting your insurer before assuming costs are entirely out of pocket. Additionally, a small number of NHS specialised commissioning pathways exist for cannabis-based medicines, though PTSD is not yet among the funded indications under current NHS England guidance.
Risks — Important Considerations
Medical cannabis is not appropriate for all PTSD patients, and a responsible prescribing approach includes a detailed risk assessment before initiation.
Cannabis can temporarily increase anxiety, particularly at higher THC doses or in patients who are THC-naive. In individuals with PTSD, where hypervigilance and anxiety are core symptoms, this effect can occasionally worsen the presenting complaint before any therapeutic benefit is established. Starting doses are kept low for this reason, and patients are advised to begin treatment during a period of relative stability rather than acute crisis.
In patients with dissociative episodes — a feature of Complex PTSD in particular — high-THC products carry a risk of exacerbating depersonalisation or derealisation. Balanced THC:CBD formulations or CBD-predominant products are generally preferred in these cases, with THC only introduced cautiously once tolerance is established.
Cannabis use is associated with increased risk of psychotic symptoms in individuals with a personal or family history of psychosis or schizophrenia. A thorough psychiatric history is therefore essential before prescribing, and cannabis-based treatment is generally contraindicated in patients with a history of psychosis.
Interactions with existing medications — particularly SSRIs and benzodiazepines — should be reviewed by the prescribing clinician. Benzodiazepine use is common in PTSD, and the sedative effects of nighttime THC products may compound this. Clinicians typically plan a gradual benzodiazepine taper as cannabis treatment is established, rather than abrupt discontinuation.
All treatment should be initiated and monitored by a registered specialist. Self-medicating with unlicensed cannabis products outside a medical framework does not carry the same safeguards and is not equivalent to a prescribed CBMP.
Frequently Asked Questions
Is cannabis prescribed for PTSD on the NHS in the UK?
Not currently. NHS England has not included PTSD among the funded indications for cannabis-based medicines under its specialised commissioning framework. All cannabis prescriptions for PTSD in the UK are currently issued privately by licensed specialist clinicians. NICE guideline NG116 recommends trauma-focused CBT and EMDR as first-line PTSD treatments, and the NHS position may evolve as more UK-generated real-world evidence accumulates.
Do I need a formal PTSD diagnosis to get a cannabis prescription?
Yes. UK prescribing clinics require documented evidence of a PTSD diagnosis from a qualified clinician — a GP letter, a psychiatric assessment or a discharge summary from NHS Talking Therapies. Self-reported symptoms alone are not sufficient. You should also be able to demonstrate that at least one conventional treatment (typically an SSRI or a course of trauma-focused therapy) has been tried and found inadequate or poorly tolerated.
Can military veterans access medical cannabis in the UK?
Yes. Veterans follow the same private prescription pathway as civilian patients. Some clinics have developed veteran-specific assessment processes. Organisations including Combat Stress and Help for Heroes can provide supporting documentation for veterans who have engaged with their services. Veterans should seek advice regarding any potential impact on benefits or pension entitlements before initiating private medical treatment.
How long does cannabis treatment for PTSD take to show results?
Most patients report initial improvements in sleep quality and nightmare frequency within the first two to four weeks of optimised dosing. Broader symptom improvements — including reductions in hypervigilance and intrusive thoughts — typically take longer to consolidate, often two to three months of consistent treatment. PCL-5 scores are usually reassessed at three and six months to evaluate treatment response objectively. Cannabis is generally considered an adjunct to, rather than a replacement for, psychological therapy.
Sources and Further Reading
- NHS: Post-traumatic stress disorder (PTSD)
- NICE Guideline NG116: Post-traumatic stress disorder
- Elms L et al. (2019). Cannabidiol in the Treatment of Post-Traumatic Stress Disorder. Journal of Alternative and Complementary Medicine
- Bonn-Miller MO et al. (2018). Cannabis use and PTSD symptoms. Frontiers in Pharmacology
- Combat Stress UK: Veterans Mental Health Charity
- Drug Science Project TWENTY21: UK medical cannabis real-world evidence registry
For more information on the full range of conditions treated with medical cannabis in the UK, visit our complete patient guide or explore medical cannabis for anxiety.
